5-Question Quiz on Immunotherapy in Melanoma

Leveraging Surgical Oncology Advances in Colorectal Cancer Care

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

May 13th 2024

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

May 6th 2024

FDA Approves Tarlatamab After Progression on Chemotherapy in ES-SCLC

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.

53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ

The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.

52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy

Related Content

Leveraging Surgical Oncology Advances in Colorectal Cancer Care

May 13th 2024

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.

May 6th 2024

FDA Approves Tarlatamab After Progression on Chemotherapy in ES-SCLC

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ

The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.